CF
AGIO icon

Cantor Fitzgerald’s Agios Pharmaceuticals AGIO Stock Holding History

Cantor Fitzgerald’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-104,200
Closed -$3.05M – 464
2025
Q1 		$3.05M Buy
+104,200
New +$3.46M 0.06% 61

Other funds holding AGIO

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Cantor Fitzgerald's AGIO Position: Q3 2025 in Review

Cantor Fitzgerald sold out of Agios Pharmaceuticals (AGIO) in Q3 2025, closing a stake of 134,200 shares — an estimated $4.46M sold.

Cantor Fitzgerald first reported a position in AGIO in Q3 2024 and held it in 3 quarters. The position peaked at $4.46M in Q2 2025. 220 funds tracked by Wall St. Rank hold AGIO as of Q3 2025.

  • Cantor Fitzgerald reported no remaining Agios Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Cantor Fitzgerald sold 134,200 Agios Pharmaceuticals shares in Q3 2025, an estimated $4.46M.
  • Cantor Fitzgerald first reported a position in Agios Pharmaceuticals in Q3 2024 and held it in 3 quarters.
  • Cantor Fitzgerald's Agios Pharmaceuticals position peaked at $4.46M in Q2 2025.
  • 220 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2025.

Based on Cantor Fitzgerald's 13F filing for Q3 2025, filed 14 Nov 2025.